Text Size

Calcium Phosphate and Incretins

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gerhard Jahreis, University of Jena
ClinicalTrials.gov Identifier:
NCT01296997
First received: February 15, 2011
Last updated: November 6, 2012
Last verified: November 2012
History of Changes
  Purpose

The study was conducted to investigate the effect of a calcium phosphate supplementation on the secretion of incretins.


Condition Intervention
Healthy Men
 Dietary Supplement: calcium phosphate
Other: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Influence of a Calcium Phosphate Supplementation on the Secretion of Incretins in Humans.

Resource links provided by NLM:

MedlinePlus related topics: Calcium
U.S. FDA Resources

Further study details as provided by University of Jena:

Primary Outcome Measures:
  • secretion of incretins [ Time Frame: 3 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • concentration of minerals in plasma [ Time Frame: 3 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 10
Study Start Date: July 2010
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: calcium phosphate Dietary Supplement: calcium phosphate
the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day
Placebo Comparator: placebo Other: placebo
the subjects consumed a bread without pentacalcium phosphate

  Eligibility

Ages Eligible for Study:   20 Years to 35 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy men

Exclusion Criteria:

  • intake of dietary supplements and chronic diseases
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01296997

Locations
Germany
Friedrich-Schiller-University Jena, Institute of Nutrition, Department of Nutritional Physiology
Jena, Thuringia, Germany, 07743
Sponsors and Collaborators
University of Jena
Investigators
Principal Investigator: Gerhard Jahreis, Prof. Dr. Friedrich-Schiller-University Jena, Institute of Nutrition, Department of Nutritional Physiology
  More Information

No publications provided by University of Jena

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Gerhard Jahreis, Prof. Dr. habil, University of Jena
ClinicalTrials.gov Identifier: NCT01296997     History of Changes
Other Study ID Numbers: LSEP H45-10
Study First Received: February 15, 2011
Last Updated: November 6, 2012
Health Authority: Germany: Ethics Commission

Keywords provided by University of Jena:
calcium phosphate
incretins
human study

Additional relevant MeSH terms:
Calcium, Dietary
Incretins
Bone Density Conservation Agents
Physiological Effects of Drugs
 Pharmacologic Actions
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on June 17, 2013